NCT06781450View on ClinicalTrials.gov

Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

April 23, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Primary Mediastinal B Cell Lymphoma
Trial Locations (3)

20133

RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

40138

RECRUITING

IRCCS Azienda Ospedaliero - Universitaria di Bologna, Bologna

70124

RECRUITING

Azienda Ospedaliera Universitaria- POLICLINICO BARI, Bari

All Listed Sponsors
lead

IRCCS Azienda Ospedaliero-Universitaria di Bologna

OTHER